The goal of this surveillance study is to collect real-world data on adults and youth with type 1 diabetes (T1D) using twiist(TM) for insulin delivery.
Study Type
OBSERVATIONAL
Enrollment
1,875
twiist(TM) system includes a novel insulin pump, a CGM sensor, and the glycemic-control algorithm
Jaeb Center for Health Research
Tampa, Florida, United States
RECRUITINGSevere hypoglycemia events
Severe hypoglycemia events with cognitive impairment sufficient to require the assistance of a third party for treatment
Time frame: From enrollment to the end of participation at 12 months
Severe hypoglycemia events associated with seizure or loss of consciousness
Time frame: From enrollment to the end of participation at 12 months
Diabetic ketoacidosis
Time frame: From enrollment to the end of participation at 12 months
Hospitalizations related to use of twiist
Time frame: From enrollment to the end of participation at 12 months
Unanticipated adverse device effects
Time frame: From enrollment to the end of participation at 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.